The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
As of today (2026-07-11), Genmab AS's 9-Day RSI is 74.14.
The industry rank for Genmab AS's 9-Day RSI or its related term are showing as below:
CHIX:GMABc's 9-Day RSI is ranked worse than 93.95% of 1421
companies
in the Biotechnology industry
Industry Median: 49.68
vs CHIX:GMABc: 74.14
Genmab AS (CHIX:GMABc) 9-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
Genmab AS 9-Day RSI Related Terms
CHIX:GMABC vs VRTX, REGN, ALNY: 9-Day RSI Comparison
For the Biotechnology subindustry, Genmab AS's 9-Day RSI, along with its competitors' market caps and 9-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genmab AS 9-Day RSI vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Genmab AS's 9-Day RSI distribution charts can be found below:
* The bar in red indicates where Genmab AS's 9-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genmab AS (CHIX:GMABC) has a 9-Day RSI of 74.14 as of Jul. 11, 2026. According to the industry distribution chart, Genmab AS ranks #1335 out of 1421 companies in the Biotechnology industry, placing it in the top 93.9%.
Is Genmab AS's 9-Day RSI too high?
Genmab AS's current 9-Day RSI is 74.14. The Biotechnology industry median 9-Day RSI is 49.68. Genmab AS's value of 74.14 is 49.2% above this industry median. Based on the distribution chart, Genmab AS ranks #1335 out of 1421 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Genmab AS has a GF Score™ of 95/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genmab AS's 9-Day RSI compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Genmab AS ranks #1335 out of 1421 companies for 9-Day RSI. This places Genmab AS in the lower half of its industry. The industry median 9-Day RSI is 49.68. Genmab AS's value of 74.14 is 49.2% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 9-Day RSI for a Biotechnology company?
The median 9-Day RSI among Biotechnology companies is 49.68, based on 1,421 companies in the industry. Companies in the top quartile (top 25%) have a 9-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 9-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Genmab AS's current 9-Day RSI of 74.14 is 49.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 9-Day RSI mean?
A high 9-Day RSI can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median 9-Day RSI is 49.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genmab AS's current 9-Day RSI is 74.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genmab AS stock overvalued right now?
Based on GuruFocus' analysis, Genmab AS (CHIX:GMABC) is currently considered Modestly Undervalued. The stock's GF Value™ is kr2,292.70, compared to a current price of kr1,859.75 — trading 18.9% below its estimated fair value. The current 9-Day RSI is 74.14 and 49.2% above the Biotechnology industry median of 49.68. Genmab AS's overall GF Score™ is 95/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 9-Day RSI calculated?
9-Day RSI is calculated from a company's financial statements. For Genmab AS (CHIX:GMABC), the current 9-Day RSI is 74.14 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genmab AS (CHIX:GMABC) Overvalued in 2026?
Based on GuruFocus' analysis, Genmab AS stock appears to be undervalued.
The current stock price of kr1,859.75 is trading 18.9% below its estimated GF Value™ of kr2,292.70.
GuruFocus considers Genmab AS to be Modestly Undervalued.
Key valuation signals for CHIX:GMABC:
9-Day RSI: 74.14
GF Value™: kr2,292.70 vs. price of kr1,859.75 (18.9% below fair value)
Industry Position: 49.2% above the Biotechnology median (#1335 of 1421)
No single metric tells the full story. See the CHIX:GMABC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
95GF Score
Get the complete analysis for CHIX:GMABC
9-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:GMABC has been successfully added to your 